---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-058235"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T16:24:16.704476+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Amgen issues $24B in senior notes to fund Horizon Therapeutics acquisition

## Summary
- Issued $24B aggregate principal across eight tranches (2025-2063 maturities) with rates 5.150%-5.750%.
- Net proceeds ~$23.77B after discounts and expenses; used to fund Horizon acquisition.
- If Horizon acquisition not consummated by Jan 31, 2024, notes subject to special mandatory redemption at 101% plus accrued interest.
- Bridge credit facility commitments reduced by net proceeds from this offering.
- Notes rank senior unsecured, effectively subordinated to subsidiary obligations.

## SEC filing metadata
- accession: 0001193125-23-058235
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312523058235/0001193125-23-058235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312523058235/d448346d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-058235
- JSON: https://secwatch.observer/filing/0001193125-23-058235.json
- Plain text: https://secwatch.observer/filing/0001193125-23-058235.txt

## Key facts
- Material Agreements
  AMGEN INC amended Bridge Credit Facility with Citibank, N.A., Bank of America, N.A..
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Citibank, N.A., Bank of America, N.A.
  source text: Following the issuance and sale of the Notes described above, the commitments under the Bridge Credit Facility have been further reduced by the amount corresponding to the Net Cash Proceeds to the Company from the Notes offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523058235/0001193125-23-058235-index.htm
- Material Agreements
  AMGEN INC entered into Officer's Certificate with The Bank of New York Mellon Trust Company, N.A. valued at $24,000,000,000 aggregate principal amount (effective 2023-03-02).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: The Bank of New York Mellon Trust Company, N.A.
  - Value: $24,000,000,000 aggregate principal amount
  - Effective: 2023-03-02
  source text: On March 2, 2023, Amgen Inc. (the “Company”) issued and sold $2,000,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2025 (the “2025 Notes”), $1,500,000,000 aggregate principal amount of the Company’s 5.507% Senior Notes due 2026 (the “2026 Notes”), $3,750,000,000 aggregate principal amount of the Company’s 5.150% Senior Notes due 2028 (the “2028 Notes”), $2,750,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2030 (the “2030 Notes”), $4,250,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2033 (the “2033 Notes”), $2,750,000,000 aggregate principal amount of the Company’s 5.600% Senior Notes due 2043 (the “2043 Notes”), $4,250,000,000 aggregate principal amount of the Company’s 5.650% Senior Notes due 2053 (the “2053 Notes”) and $2,750,000,000 aggregate principal amount of the Company’s 5.750% Senior Notes due 2063 (the “2063 Notes” and, together with the 2025 Notes, the 2026 Notes, the 2028 Notes, the 203
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523058235/0001193125-23-058235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.